MBX Biosciences (MBX) Return on Capital Employed (2024 - 2026)

MBX Biosciences has disclosed Return on Capital Employed across 3 years of filings, most recently posting 24.43% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 24.43%, up 856.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 24.43% (up 856.0% YoY), and the FY2025 annual result was 31.49%, up 976.0% from the prior year.
• Return on Capital Employed came in at 24.43% for Q1 2026 at MBX Biosciences, up from 26.0% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 24.43% in Q1 2026 to a low of 38.14% in Q2 2025.
• The 3-year median for Return on Capital Employed is 27.96% (2025), against an average of 29.54%.
• Across the five-year window, Return on Capital Employed fell 21 bps in 2025 and jumped 856 bps in 2026, its largest moves.
• MBX Biosciences' Return on Capital Employed stood at 25.79% in 2024, then decreased by 1 bps to 26.0% in 2025, then grew by 6 bps to 24.43% in 2026.
• The last three Return on Capital Employed figures came in at 24.43% (Q1 2026), 26.0% (Q4 2025), and 29.92% (Q3 2025), per Business Quant data.